Fabrazyme 35 mg, powder for concentrate for solution for infusion
- Name:
Fabrazyme 35 mg, powder for concentrate for solution for infusion
- Company:
Sanofi Genzyme
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/02/21

Click on this link to Download PDF directly
Sanofi Genzyme
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 8 April 2021 Ed-HCP
Reasons for updating
- Replace document
Updated on 8 April 2021 Ed-Ptnt
Reasons for updating
- Replace document
Updated on 6 April 2021 SPC
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 3 March 2021 Ed-Both
Reasons for updating
- Add New Doc
Updated on 12 February 2021 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 2 - excipient warnings
Updated on 23 November 2020 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 23 November 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 2 - excipient warnings
Free text change information supplied by the pharmaceutical company
Updated on 6 July 2020 PIL
Reasons for updating
- XPIL Removed
Updated on 10 June 2020 Ed-HCP
Reasons for updating
- Replace document
Updated on 10 June 2020 Ed-Ptnt
Reasons for updating
- Replace document
Free text change information supplied by the pharmaceutical company
Correction of document
Updated on 18 February 2020 PIL
Reasons for updating
- Improved presentation of PIL
Updated on 10 February 2020 Ed-HCP
Reasons for updating
- Add New Doc
Updated on 10 February 2020 Ed-Ptnt
Reasons for updating
- Add New Doc
Updated on 7 February 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 7 February 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 24 December 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
Updated on 16 September 2019 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 7 January 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
Updated on 7 January 2019 SPC
Reasons for updating
- Change to section 4.9 - Overdose
- Change to section 7 - Marketing authorisation holder
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.7 Effects on ability to drive and use machines
Fabrazyme may have a minor influence on the ability to drive or use machines on the day of Fabrazyme administration because dizziness, somnolence, vertigo and syncope may occur (see section 4.8).
7. MARKETING AUTHORISATION HOLDER
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands
Updated on 18 May 2018 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 18 December 2017 PIL
Reasons for updating
- Improved presentation of PIL
Updated on 18 December 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 11 December 2017 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 11 December 2017 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 3 November 2017 PIL
Reasons for updating
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 17 July 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Introduction of new strength
Updated on 15 May 2017 SPC
Reasons for updating
- Addition of joint SPC covering all presentations
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 19 August 2014 PIL
Reasons for updating
- Addition of manufacturer
- Addition of information on reporting a side effect.
Updated on 31 August 2012 PIL
Reasons for updating
- Removal/change of distributor
Updated on 15 December 2011 PIL
Reasons for updating
- Change to, or new use for medicine
- Change to warnings or special precautions for use
- Change to side-effects
- Change to drug interactions
- Change to information about pregnancy or lactation
- Change to date of revision
- Change to improve clarity and readability
Updated on 17 June 2011 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 16 April 2010 PIL
Reasons for updating
- New PIL for medicines.ie
Patient Log BookRisk Minimisation Materials
(Click to Download)
HCP GuideRisk Minimisation Materials
(Click to Download)
Educational Materials for Medicines
Educational Materials for Medicines
Patient Log BookRisk Minimisation Materials
(Click to Download)
Patient GuideRisk Minimisation Materials
(Click to Download)
Educational Materials for Medicines
Educational Materials for Medicines